Want to see VERA full AI Analyst Report?
VERA Stock Chart & Stats
$35.45
$0.05(0.14%)
At close: 4:00 PM EDT
$35.45
$0.05(0.14%)
Day’s Range― - ―
52-Week Range$21.15 - $56.05
Previous CloseN/A
Volume472.67K
Average Volume (3M)2.16M
Market Cap
$2.33B
Enterprise Value$2.66K
Total Cash (Recent Filing)$499.16M
Total Debt (Recent Filing)$75.23M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 11, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.86
Shares Outstanding72,063,330
10 Day Avg. Volume1,702,990
30 Day Avg. Volume2,159,832
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$78.00Price Target Upside120.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.29
Revenue Forecast (FY)$25.55M
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA accelerated approval and a commercial launch materially de-risks Vera’s lead program by establishing a regulatory and market foothold. As a marketed therapy, TRUTAKNA creates a path from R&D to revenue, enables real-world data generation, and supports commercialization infrastructure and payer engagement over coming quarters.
Clearer Full-Approval PathwayAn agreed earlier analysis plan for the ORIGIN 3 eGFR endpoint accelerates the timing and reduces regulatory uncertainty for full approval. This structural change can shorten the timeline to a supplemental filing, clarify development milestones, and improve predictability for commercialization and partner negotiations.
Modest Leverage On Balance SheetRelatively low leverage provides financial flexibility for a clinical-stage biotech dependent on external funding. Meaningful equity on the balance sheet cushions near-term operations, lowers immediate solvency risk versus peers with higher debt, and supports strategic options like partnerships or staged commercial investment.
Bears Say
No Commercial RevenueVERA remains largely pre-commercial; absence of recurring product sales means cash needs are driven by development spend and milestones. Heavy and widening net losses create sustained funding pressure, making long-term sustainability reliant on successful commercialization, milestone receipts, or dilutive financings.
Severe Cash BurnLarge, worsening negative operating and free cash flow indicate the business cannot self-fund operations. Persistent cash burn increases the probability of additional equity or debt raises, which can dilute shareholders and constrain the company’s ability to invest in broad commercial rollouts or multiple indications concurrently.
Unproven Commercial Margin ProfileWith no historical product sales, margin structure, pricing power, and real-world uptake remain untested. Achieving sustained profitability depends on successful market access, reimbursement, and demand for a niche IgA nephropathy indication, leaving long-term margin sustainability and scalability uncertain.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $21.15 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $2.33B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on Aug 10, 2026. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.576 by $0.056.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.61.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 72,063,330 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.576. Following the earnings report the stock price went down -4.085%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.00 (120.03% Upside)
$78.00 (120.03% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 201.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.87%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA Stock 12 Month Forecast
Average Price Target
$78.00
▲(120.03% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
8.97% Insiders
16.92% Mutual Funds
51.20% Other Institutional Investors
7.42% Public Companies and
Individual Investors